The POWER-PAK Score Characterizes Tumor Response to 3 Months of Preoperative Endocrine Therapy.

ABSTRACT:

Background

The Pre-Operative Window of Endocrine Therapy to Inform Radiation Therapy Decisions (POWER, NCT04272801) trial aims to determine whether 3 months of preoperative endocrine therapy (pre-ET) informs adjuvant radiation therapy decisions among older women with early stage, ER-positive breast cancer. We propose the POWER Pathologic Assessment and Ki-67 (POWER-PAK) scoring system to characterize the histologic effects of pre-ET.

Methods

Histologic evaluation was performed on core biopsy and lumpectomy specimens from 37 POWER trial participants who completed pre-ET and surgery. The POWER-PAK score consists of tumor regression, decrease in Ki-67 expression, and ER expression, each ranging from 0 to 2. Scores were aggregated to create the POWER-PAK score with a range from

SUBMITTER: Meneveau MO 

PROVIDER: S-EPMC10766409 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature